KRAS and cancer: Since changes in genetic profiles and percentages of mutant alleles in ctDNA have been reported to serve as an early sign of treatment response or cancer progression [11], we hypothesized that the detection of low-frequency KRAS mutations in plasma ctDNA of mCRC patients might have clinical value in disease prognostication and might provide guidance for further decision making.